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Co-inhibitory molecules such as PD1, PD-L1 and
CTLA-4 are being increasingly used as targets of thera-
peutic intervention against cancer. The use of monoclo-
nal antibodies targeting these immune checkpoints has
been shown to promote anti-tumor immune responses
clinically. While these promising results have led to a
critical paradigm shift in treatments for cancer, these
approaches are also plagued with limitations owing to
cancer immune evasion mechanisms and adverse toxici-
ties associated with continuous treatment. It has been
difficult to reproduce and develop interventions to these
findings preclinically for many reasons including spe-
cies/age-related differences in expression of these mar-
kers, poor tumor modeling, and reagent xenogenicity. In
this study, we investigated adverse effects in mice receiv-
ing repeated anti-PD1 (clone J43) or PD-L1 (clone
10F.9G2) monoclonal antibody (mAb) administration in
the 4T1 mouse model of mammary carcinoma. Mice
bearing day 14 syngeneic mammary carcinomas were
treated with mAbs to PD1 or PD-L1 which are of rat or
hamster origin respectively. Control mice received rat
IgG or hamster IgG mAb. Repeat administration of 250
mg i.p. of anti-PD1 or 200 mg i.p. of anti-PD-L1 into
tumor bearing mice led to mortality in 50-100% of trea-
ted mice within 10 days of the initiation of treatment
whereas mice receiving the control mAbs exhibited
complete survival at equivalent doses. These toxicities
were observed within 1-5 hours of administration of the
final dose. Consistent with anaphylaxis, symptoms
including piloerection, periorbital puffiness and dyspnea
were observed prior to mortality. Furthermore, spleens
of mice treated with anti-PD1 were observed to be
greater in size relative to untreated mice indicating
increased myelopoiesis. Previously, 4T1 has been asso-
ciated with high expression of granulocyte-colony stimu-
lating factor (G-CSF) systemically resulting in increased
extramedullary hematopoiesis and the accumulation of
myeloid derived suppressor cells (MDSCs). Both G-CSF
and MDSCs have been shown to play an exacerbating role
in anaphylactic reactions. Our observations here suggest
that the foreign nature of anti-PD1 and anti-PD-L1 along
with their important role in checkpoint blockade com-
bined with tumor-induced immune modulation may pro-
mote an anaphylaxis-like response in tumor-bearing mice.
This study highlights the importance of species-specific
mAbs for preclinical models as well as the interesting
roles of both checkpoint blockade and tumor-dependent
immunomodulation contributing to this particular class of
cancer immunotherapy.
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